BIBF 1120
Phase 3Small molecule
Boehringer IngelheimBIBF 1120 is one of 359 small molecule programs targeting Glioma. It is currently in Phase 3.
14
Indications
44
Total Trials
0
Active Trials
358
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1BIBF 1120
Boehringer IngelheimPhase 3
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Zinecard
CChildren's Oncology Group
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Nubain
AAultman Health Foundation
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ovarian Cancer5 trials
Small Cell Lung Cancer4 trials
Advanced Solid Tumours4 trials
Lung Cancer3 trials
22 more indications
Idiopathic Pulmonary Fibrosis3 trials
Hepatocellular Carcinoma2 trials
Elderly Patients1 trial
Malignancies1 trial
Colorectal Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Multiple Myeloma1 trial
Fallopian Tube Carcinoma1 trial
Maximum Tolerated Dose1 trial
Gemcitabine1 trial
Intravenous1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BIBF 1120. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company